The İEİS (Pharmaceutical Manufacturers Association) assessment based on IQVIA data shows the Turkish pharmaceutical market reaching TRY 430.8 billion in value and 2.7 billion boxes in volume in 2025, with nominal growth of 32.7%. But the headline alone does not explain the market: the composition of growth, the segment splits and the trade balance are the real inputs of market access strategy. This article reads the 2025 picture across every split and draws the strategic lessons for companies.
TRY 430 billion in a ten-year series: the anatomy of 2,354% nominal growth
Between 2015 and 2025 the market rose from TRY 17.6 billion to TRY 430.8 billion — roughly 2,354% nominal. Reading the series requires separating three dynamics: the FX and price effect (pricing-euro-rate increases and list-price revisions), the mix effect (shift from low-priced to high-priced products) and the volume effect (box growth). In 2025 the overwhelming share of growth came from price and mix: FX-driven price increases contributed roughly 80% of growth; the shift towards higher-priced products added 9.6 points (TRY 31.2 billion); volume contribution stayed limited. The most striking finding is on the new-product side: despite 342 new medicines entering the market, new products contributed only 2 points (TRY 6.5 billion) to total growth. This limited share is launch delays and access barriers reflected in market data — the numerical proof of the market access profession's raison d'être.
Originator-generic balance: value originator, volume generic
In 2025 the originator market reached TRY 272.7 billion — about two-thirds of value — while the generic market hit TRY 158.1 billion. The split delivers its real message in shares: generics hold 36.7% of value but 64.3% of boxes; originators 63.3% of value and 35.7% of boxes. This asymmetry summarises the market's character: volume-heavy generic, value-heavy originator. For generic companies, value growth cannot be isolated from volume growth; exports, new formulations and complex generics are the instruments of the value ladder. For originator companies, how this balance shifts after patent expiry — including biosimilar penetration — sits at the centre of portfolio strategy.
Import-domestic split: localisation strong in volume, imports heavy in value
In 2025 domestically produced medicines reached TRY 238.6 billion and 2.46 billion boxes; imported medicines TRY 192.1 billion but only 0.19 billion boxes. Local production covers the overwhelming share of boxes, while imports concentrate in a small slice with very high average unit value: technology-intensive, new-generation products are largely imported. This picture shows the gap localisation policies target: localisation of value. Technology-transfer agreements, in-country manufacturing commitments and localisation criteria in public procurement are the instruments for closing it; for global companies, the cost-benefit of making Türkiye a base country (clinical research, manufacturing, export hub) should be read from this split.
Biologics and biosimilars: the edge of a TRY 90 billion wave
The biologics market reached TRY 90.9 billion and 33.3 million boxes in 2025. The split is striking: reference biologics TRY 82.7 billion (21.6 million boxes) versus biosimilars TRY 8.2 billion (11.7 million boxes). The biosimilar value share remains around 9%, with a higher volume share. This marks two strategic arenas. First, the acceleration potential of biosimilar penetration: tenders (TAS) and payer practice will determine penetration; biosimilar companies should synchronise marketing and supply strategy with the reference products' patent-expiry calendar. Second, lifecycle management for reference biotech companies: differentiation, rebates and supply-guarantee models to protect share ahead of expiry.
Foreign trade: USD 2.51 billion exports and a regional-base identity
Pharmaceutical exports closed 2025 up 9.3% at USD 2.51 billion; over 2015-2025 exports grew 128.7%, reaching more than 180 countries. On the import side, the high-technology product weight keeps the current deficit in place; the imported market's TRY 192 billion value signals the import bill's scale indirectly. With over 300 manufacturing facilities and direct employment above 80,000 (150,000+ including indirect), the sector is a priority of industrial policy. Export performance combined with Türkiye's logistical advantage at the Europe-Asia-Africa intersection cements the "regional base" identity; global companies assigning production and export roles to their Turkish operations also gain flexibility in access negotiations.
The institutional ecosystem: who produces the data
The ecosystem producing this data shapes how the field reads it: İEİS (manufacturer-weighted association) with monthly market bulletins and annual assessments; AİFD (research-based companies) with the Türkiye Pharmaceutical Sector Report together with EFPIA; TİSD and TEİS representing devices and pharmacy. IQVIA data is the international standard of market measurement. For market access teams, following this ecosystem means knowing the data's methodology — whether measured at manufacturer or pharmacy prices; the same market can appear in different sizes under different methodologies.
The sustainability of growth: what remains when the price dynamic exhausts itself?
If most of 2025 growth was price-driven, the critical question is: when FX updates normalise, what is the market's structural growth? In a market with limited volume growth — absent ageing and chronic-disease burden, no strong volume driver — sustainable value growth must come from innovation. Yet a 2-point new-product contribution shows innovation hitting access bottlenecks. The lesson for companies: every month invested in launch preparation should be priced as market-share loss; the length of the post-licensing reimbursement process directly determines a product's first year on the market.
Strategic lessons from the 2025 data
- Value growth is a window: the price space opened by FX updates must be used in step with reimbursement strategy; a price increase alone is no access guarantee.
- Position by split: knowing your product's place in the originator/generic, import/domestic and biologics splits is the starting point of pricing and access argumentation.
- Track localisation criteria: localisation rules in public procurement and support programmes feed supply-chain and manufacturing decisions.
- Prepare for the biosimilar wave: the size of the biologics market pushes patent-expiry strategies (differentiation, tenders, price corridors) forward.
- The export argument: your Turkish operation's export contribution is a public-value argument that strengthens your negotiating position with the payer.
Milestones in the 2015-2025 series
Segmenting the series reveals the market's regime changes. 2015-2017 (FX-pressure era): with the pricing euro rate lagging, value growth stayed limited; the first waves of supply and availability problems. 2018-2021 (FX-correction era): years when nominal growth accelerated with large FX steps while parallel export and availability crises peaked. 2022-2024 (search for stepped updates): beginning with a double FX increase and moving to single annual steps; years of intense price revisions in Annex-4/C and imports, and heavy use of continuity mechanisms (Annex-1 supply, special import). 2025 (the new balance): price effect as the overwhelming source of growth in a TRY 430 billion market; box growth remaining at ~3-4%. A company that knows this series builds its 2026 plan not on an "FX-step year" assumption but on a mix-and-innovation year.
Therapy areas and demand dynamics
In the distribution of value across therapy areas, oncology, metabolic-endocrine, nervous system, blood and blood-forming organs, and gastrointestinal-metabolic areas lead. Structural dynamics steer: in oncology, new-generation targeted therapies and immunotherapies grow both value and treatment duration; in metabolic-endocrine, diabetes and obesity products (especially the GLP-1 agonist class) are among the fastest-growing value slices as the global trend's Turkish reflection; in the nervous-system group, rare-disease therapies and mAbs are decisive. Portfolio planning should track this distribution: where value grows, where volume contracts, where biosimilar/competitive-generic pressure rises — the answers are the market side of pipeline prioritisation.
The distribution channel and pharmacy economics
The pharmacy channel is decisive in Turkish distribution: prescription consumption flows largely through pharmacy sales paid by the public payer. Wholesaler-pharmacist shares in drug prices are set by legislation; FX steps and rebate changes directly affect channel economics. In a country of roughly thirty thousand pharmacies, field-force design (visit frequency, order-supply flow) is the daily face of availability management. Availability is a KPI as critical as share: a treatment interruption is both a patient-safety and a payer-trust matter; supply-chain planning (allocation, stock policy, parallel-export risk) therefore belongs within market access responsibility.
2026 expectations: what to watch
- The FX regime: if stepped updates persist, value growth stays price-driven; the steps' spacing and size are the main uncertainty.
- New-product contribution: whether the entry performance of 342 new products holds; whether launch-access times shorten.
- Biosimilars/tenders: accelerating share movements in the biologics market; hardening lifecycle strategies of reference products.
- Localisation: growing weight of technology transfer and manufacturing commitments on the public agenda; exports growing with the base-country ambition.
- Rare diseases and high-cost therapies: intensifying debates on SUT indication articles and alternative payment models.
A guide to working with market data: which data for which question?
Market data earns its value when tied to the right question. Launch prioritisation: therapy-area size and growth, competitive intensity, access times (waiting/listing durations of comparable products). Territory and field planning: geographic sales distribution, pharmacy/wholesaler density maps, prescription profiles. Pricing files: comparator prices, rebate levels, negotiation precedents. Reimbursement files: market-share scenarios (fast/medium/slow penetration), market assumptions of budget-impact calculations. Management reporting: value/box growth decomposition, price-mix-volume analysis. Companies that institutionalise this mapping do not merely buy data and shelve the report; every data purchase becomes the input to a decision. Practical advice: format market-data presentations as "decision page + data annex" — the first page stating which decision changes.
Strategic consequences of the box-value asymmetry
The volume-generic, value-originator structure has consequences at three levels. Company level: originators protect value while facing volume pressure; generic leaders in volume seek ladders of value (exports, complex generics, biosimilars). Product level: for high-unit-price products, availability is not how many pharmacies stock the box but reaching the right patient at the right moment; in rare diseases and oncology, logistics and allocation management are the sale itself. System level: value concentrating in a few high-price products compresses the reimbursement agenda each year into a handful of large budget-impact decisions — systematising the debate on alternative payment models and risk sharing. An access team reading the three levels together knows in advance which products will carry the year's budget debates.
Data sources and methodology warnings
Three methodological cautions when reading market data. Caution 1 — price level: is the data presented at manufacturer (ex-factory) or pharmacy prices? The two levels can differ 15-20% in a year; even growth rates diverge. Caution 2 — scope: does the dataset cover out-of-hospital (pharmacy) sales or hospital sales? In SUT-covered therapies the hospital channel can carry significant weight. Caution 3 — timing: at which month are annual figures cut; with in-year FX steps, at which rate is annual growth computed? A team that asks none of these questions tries to draw right strategy from the wrong table. Good practice: request the methodology page with every external data purchase and keep the series used in internal analysis in a single source.
Step by step: from market data to strategy
Turning market data into strategy is a six-step discipline. Step 1 — Framing: which decision is being supported (launch priority, price position, field scale)? Data without a decision is a shelved report. Step 2 — Data selection: the splits the decision needs (therapy area, region, payer/private, originator/generic), with the methodology page. Step 3 — Decomposition: split growth into price/mix/volume/new-product components; the 2025 finding of ~80% price effect is this step's product. Step 4 — Scenarios: three scenarios (conservative/base/optimistic) for FX steps, access times and biosimilar dynamics. Step 5 — Product mapping: place your portfolio on the same market table; for each product, whether the market wind is behind or against. Step 6 — Action and calendar: translating the strategic read into action — which file accelerates, which product enters which negotiation. In companies that institutionalise the discipline, market data becomes not a report but a decision input.
2026 planning scenarios: three tables
Planning requires drawing three tables. Table A — the FX-step table: announced and expected 2026 steps; portfolio list- and net-price effect at each step. This table sets the calendar of price operations and wholesaler-pharmacy communication. Table B — the access-time table: for each portfolio product, historical and forecast licensing-to-reimbursement durations, benchmarked against comparable products. The table shows the start date of launch preparation and the "cost of waiting" (the market-share equivalent of each month). Table C — the competition table: per therapy area, the patent-expiry calendar, expected biosimilar/generic entries and payer pressure; your products' lifecycle position. Together the three tables give the skeleton of the 2026 budget and access plan: which product defends, which attacks, which transforms. Refreshed twice a year, these tables are the market team's most valuable strategic asset.
Sources and key takeaways
Core sources: İEİS market assessments based on IQVIA data; the AİFD/EFPIA Türkiye Pharmaceutical Sector Report; TÜİK foreign-trade statistics. Recommended monitoring: İEİS monthly bulletins, IQVIA quarterly data (corporate subscriptions) and annual association reports — always request methodology pages. Our key takeaways: (1) read 2025's 32.7% growth by composition — ~80% price, only 2 points new products; (2) the box-value asymmetry (generic volume, originator value) is strategy's two-front reality; (3) the biosimilar value share (~9%) sits at an acceleration threshold; (4) exports (USD 2.51 billion) are Türkiye's base-country argument — use them at the payer table; (5) market data without a decision page is a shelved report — we recommend the three-table discipline (FX, access time, competition).
Practical summary: reading the market like an access team
Compressing this article into working habits: (1) read every growth figure by decomposition — separate price, mix, volume and new-product contributions before celebrating or worrying; (2) keep the three-table discipline (FX steps, access times, competition) and refresh it twice a year; (3) treat exports as a negotiation asset — your Turkish operation's contribution to the country's pharmaceutical exports is a public-value argument at the payer table; (4) watch the biosimilar share as an early indicator: the ~9% value share sits at the threshold where tender dynamics and lifecycle strategies harden; (5) never read a market number without its methodology page — price level, scope and cut-off date change the story; (6) connect each data purchase to a decision page — market data that changes no decision is expensive wallpaper. Teams that turn these habits into routine stop reacting to the market and start positioning ahead of it; in a market where price carries growth, the durable advantage belongs to whoever converts data into earlier, better-informed access decisions.
Conclusion
Read by its composition, the TRY 430 billion market tells a clear story: the era of price-driven growth must hand over to innovation-driven growth — and the carrier of that handover is fast, evidence-based market access. To translate market data into your product's potential, position by the splits and plan launch readiness on this data, see our market analysis service and reach out.
A final note: in a market where price carries growth, data literacy compounds like interest. Teams that decompose every figure, maintain the three-table discipline and tie each data purchase to a decision do not merely report the market — they anticipate it. The 2025 numbers showed how much of the market's motion comes from policy variables; the durable advantage ahead will belong to whoever reads those variables earliest and converts them into access decisions with confidence. Treat this article's habits not as analytics hygiene but as the quiet engine of your next launch's timing.